Kymera Investor Presentation Deck
●
●
●
●
●
●
IRAK4 Degrader Best-in-Class Potential in Immune-inflammation
Potential for Broad Activity Across Th1-Th17 and Th2 Diseases
KT-474
IL-1R/TLR
Lupus
IBD
Gout
Psoriasis
IRAK4
OC
Th1-Th17/Neutrophils
Hidradenitis Suppurativa
Rheumatoid Arthritis
●
●
●
●
Th2/Eosinophils
Atopic Dermatitis
Asthma
COPD
CRSWNP
Combined global
drug sales
~$120B
Source: 1. GlobalData; 2. Evaluate Pharma;.3. Ahn. JAMA Otolaryngol Head Neck Surg. 2016; 4. Dash. Allied
Market Research 2021
KYMERA ©2023 KYMERA THERAPEUTICS, INC.
Indication
AD
HS
RA
SLE
IBD
Gout
Psoriasis
Asthma
COPD
CRSWNP
●
2022 Prevalence¹
(US/EU5/JP)
98 M
785 K
6.4 M
550 K
3.1 M
20.3 M
15.8 M
86.8 M
61.9 M
20.4 M³
2022 Global Sales²
$8.6 B
$1.0 B¹
$27.9 B
$1.8 B
$23.6 B
$1.1 M
$24.6 B
$17.7 B
$9.6 B
$2.6 B4
Limitations of Current Therapies
Anti-Cytokine/Cytokine Receptor Antibodies
o Target only 1-2 cytokines
o Require injection
Small Molecule Inhibitors
o Limited pathway blockade (IRAK4 SMI)
o Safety issues (JAK family)
PAGE 9View entire presentation